http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
한국에 있어서의 Hepatitis Associated Antigen 각종 간장질환에 있어서
정환국(W. K. Chung),김부성(B . S . Kim),최제하(J. H. Choi),기춘석(C. S. Kee) 대한소화기학회 1971 대한소화기학회지 Vol.3 No.2
N/A For the purpose of clarifying the incidence of hepatitis associated antigen and its relation to the liver diseases in Korea, 64 patients who were hospitalized at St. Marys Hospital, Catholic Medical. College, Seoul, and had biopsy proven various kinds of liver diseases, were selected and submitted, to the study. The results obtained were as follows: 1. Hepatitis associated antigen was encountered most frequently in the sera of subacute hepatitis (50%) and chronic active hepatitis (36. 8%), less commonly in acute viral hepatitis (14. 3%). The remaining patients v;ith other forms of )iver diseases includding cirrhosis did not exhibit hepatitis associated antigen in the serum, 2. The incidence of positive hepatitis associated antigen was higher in active type with high serum transaminase level among chronic hepatitis patients. 3, The familiar occurrence of chronic liver diseases including cirrhosis was found in 4 out of 7 cases of hepatitis associated antigen positive chronic active hepatitis.
성인에 있어서의 혈장제 백신의 면역 지속성과 면역 증강 반응
선희식(H . S . Sun),정규원(K . W . Chung),김부성(B . S . Kim),노재철(J . C . Rho),정환국(W . K . Chung) 대한내과학회 1987 대한내과학회지 Vol.32 No.6
N/A To find out the persistence of the anti-HBs level in adult recipients after primary immunization with a vaccine and secondary boosting responses with another vaccine, we screened subjects who had no HBsAg, anti-HBs and anti-HBc before immunization with radioimmunoassay technique, and submitted them to primary immunization with a plasma-derived vaccine and secondary boosting with another plasma derivative. Finally, we could select 36 subjects who were possible to complete the follow-up study until after secondary boosting. The primary booster injection was performed at 6 months and secondary boosting at the 25th month after initial vaccination. Among 11 recipients, in whom antibody levels were increased by, more than 9,9 R.U. after primary boosting with 3 μg dose of vaccine prepared by A. Co. (V.A.) (well responders), anti-HBs levels decreased in all recipients at the 25th month after first vaccine treatment, and 4 of these showed negative seroconversion. In another 11 recipients, who had no antihody responses after inadequate primary vaccine treatment with V.A. (non-responders), no anti-HBs was found in their blood 25 months after vaccine initiation. At one month after secondary booster injection with 20 pg dose of hepatitis B vaccine provided by B. Co. (V. B.), a marked rise of anti-HBs titer was observed in all 11 well responders, and 6 of the 11 non-responders also responded. Among participants in this study, 14 who responded to primary immunization with V.B. but in whom no primary boosting effect was seen, 3 showed sero-negative conversion 25 months after vaccine initiation. A rise of more than 9.9R.U. of anti-HBs, after the secondary booster injection with V.A., was observed in 6 of the 14 subjects even in sero-negative cases.